Aurora Cannabis subsidiary Safari Flower Company has earned European Union Good Manufacturing Practice certification for its 59,000-square-foot Ontario facility in the Niagara Region, a three-year term that supports its role as a supplier to international medical cannabis markets. The certification comes shortly after Aurora acquired Safari in April 2026, strengthening its global manufacturing network and capacity to meet stringent quality, safety, and regulatory standards for markets such as Germany, Poland, and the UK. Company leadership emphasized that EU-GMP certification reinforces Safari’s ability to serve regulated markets with high compliance requirements, signaling broader export opportunities for Aurora’s medical cannabis operations. Market context notes Safari’s parent company, Aurora Cannabis Inc., trades on NASDAQ and TSX as ACB, with recent analyst views described as mixed due to ongoing revenue and profitability challenges; some analysts see the EU-GMP milestone as a positive signal amid this backdrop. Collectively, the announcements position Safari and Aurora to capitalize on growing European demand for medical cannabis while expanding their international footprint and manufacturing capabilities.